objective response rate
- Health
Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent
Darmstadt, Germany: US National Cancer Institute led Phase II clinical study met its primary objective with 36% confirmed ORR, and…
Read More »